Latest Biologic Stories
In the wake of the Food and Drug Administration’s first approval for a biosimilar product, pharma industry experts offer advice on how payers can prepare for this new class of drugs in the March
Pivotal Results Comparing Brodalumab With Stelara® (Ustekinumab) and Placebo to be Presented in Late-Breaking Session THOUSAND OAKS, Calif., March 17, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN)
CE Class Focuses on Fundamentals of Biosimilars EAST ELMHURST, N.Y., March 16, 2015 /PRNewswire/ -- With the U.S.
If authorized, SB2 will be marketed in Europe by Biogen Idec INCHEON, South Korea, March 13, 2015 /PRNewswire/ -- Samsung Bioepis Co., Ltd., today announced that the Marketing Authorization
According to the new report from BCC Research, the global biosimilars market was valued at $1.8 billion in 2013 and nearly $2.0 billion in 2014.
SAN DIEGO, March 10, 2015 /PRNewswire/ -- Halozyme Therapeutics, Inc.
-- Conference Call Scheduled for Monday, March 16, 2015, at 8:30 a.m.
WASHINGTON, March 6, 2015 /PRNewswire-USNewswire/ -- The Alliance for Safe Biologic Medicines today commended the U.S.
LAKE FOREST, Ill., March 6, 2015 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), applauds Sandoz and the U.S.
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.